Samyang Biopharm Overview
- Year Founded
-
1995
- Status
-
Public
- Stock Symbol
-
0120G0
- Investments
-
2
- Share Price
-
$30.06
- (As of Monday Closing)
Samyang Biopharm General Information
Description
Samyang Biopharm Corp develops, manufactures, and supplies medical devices, pharmaceutical products, and gene - therapeutics, aiming to deliver healthcare solutions.
Contact Information
Website
www.samyangbiopharm.comCorporate Office
- 295, Pangyo-ro, Bundang-gu
- Seongnam, Gyeonggi 13488
- South Korea
Corporate Office
- 295, Pangyo-ro, Bundang-gu
- Seongnam, Gyeonggi 13488
- South Korea
Samyang Biopharm Stock Performance
As of 16-Nov-2026, Samyang Biopharm’s stock price is $30.06. Its current market cap is $224M with 7.44M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $30.06 | $30.24 | $15.80 - $100.39 | $224M | 7.44M | 56.1K |
Samyang Biopharm Financials Summary
As of 31-Dec-2024, Samyang Biopharm has a trailing 12-month revenue of $101M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 |
|---|---|---|
| Revenue | 101,287 | 101,287 |
Samyang Biopharm Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Samyang Biopharm Patents
Samyang Biopharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026192441-A1 | Nanoparticle composition for lung-selective drug delivery | Pending | 13-Mar-2025 | ||
| WO-2026186988-A1 | Cationic lipid, method for preparing same, and composition of nanoparticles for drug delivery comprising same | Pending | 04-Mar-2025 | ||
| WO-2026142373-A1 | Novel compound having targeting site introduced through biodegradable linker and method for preparing same | Pending | 27-Dec-2024 | ||
| WO-2026142012-A1 | Lipid, preparation method therefor, and composition of nanoparticles for drug delivery comprising same | Pending | 26-Dec-2024 | ||
| WO-2026127599-A1 | Novel lipid and method for preparing same | Pending | 10-Dec-2024 | C07C335/02 |
Samyang Biopharm Investments & Acquisitions (2)
Samyang Biopharm’s most recent deal was a Merger/Acquisition with Medichem (Medical Supplies). The deal was made on 01-Jan-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Medichem (Medical Supplies) | 01-Jan-2017 | Merger/Acquisition | Medical Supplies | ||
| JB Financial Group | 17-Jan-2014 | PIPE | Holding Companies |
Samyang Biopharm ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Distribution
Subindustry
Rank
Percentile
Samyang Biopharm FAQs
-
When was Samyang Biopharm founded?
Samyang Biopharm was founded in 1995.
-
Where is Samyang Biopharm headquartered?
Samyang Biopharm is headquartered in Seongnam, South Korea.
-
What industry is Samyang Biopharm in?
Samyang Biopharm’s primary industry is Surgical Devices.
-
Is Samyang Biopharm a private or public company?
Samyang Biopharm is a Public company.
-
What is Samyang Biopharm’s stock symbol?
The ticker symbol for Samyang Biopharm is 0120G0.
-
What is the current stock price of Samyang Biopharm?
As of 16-Nov-2026 the stock price of Samyang Biopharm is $30.06.
-
What is the current market cap of Samyang Biopharm?
The current market capitalization of Samyang Biopharm is $224M.
-
What is Samyang Biopharm’s current revenue?
The trailing twelve month revenue for Samyang Biopharm is $101M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process